Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection
| Autor: | S Brinkley, Thomas D. Schiano, S Posner, Valérie Martel-Laferrière, Douglas T. Dieterich, Ponni V. Perumalswami, Mark S. Sulkowski, A. Stivala, Kian Bichoupan, Andrea D. Branch |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
business.industry Health Policy Hepatitis C virus Ribavirin Alpha interferon Hepatitis C Odds ratio medicine.disease_cause medicine.disease Gastroenterology Telaprevir chemistry.chemical_compound Infectious Diseases chemistry Internal medicine Immunology Coinfection Medicine Pharmacology (medical) business Viral load medicine.drug |
| Zdroj: | HIV Medicine. 15:108-115 |
| ISSN: | 1464-2662 |
| DOI: | 10.1111/hiv.12086 |
| Popis: | Objectives Pegylated-interferon/ribavirin dual therapy for hepatitis C virus (HCV) infection has a lower sustained virological response (SVR) rate in HIV/HCV-coinfected patients than in HCV monoinfected patients, but little is known about the relative effectiveness of teleprevir-based triple therapy in the two groups. Methods Data on 33 coinfected and 116 monoinfected patients were analysed on an intention-to-treat basis. SVR12 was defined as undetectable HCV RNA at week 12 post-end-of-treatment, severe anaemia as haemoglobin ≤ 89 g/L or a drop of ≥ 45 g/L, and advanced fibrosis/cirrhosis as Fib-4 ≥ 3.25. All coinfected patients had well controlled HIV infection. Results The groups were similar in age, gender, percentage with Fib-4 ≥ 3.25 and HCV viral load, but differed in previous treatment response, with more coinfected patients being nonresponders or treatment-intolerant (75.8% vs. 50.0% for monoinfected patients; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|